AKESO's stock plummeted 5.69% during intraday trading, giving back gains from the previous session.
The sharp decline comes despite the recent release of positive Phase II clinical data for its PD-1/CTLA-4 bispecific antibody at a major medical conference. Market participants have raised concerns over the company's broader fundamentals, including questions about the differentiation of its pipeline versus combination therapies, reported friction with its commercialization partner, and a cash runway estimated at slightly over one year, which overshadowed the favorable clinical results.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments